David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Fase I-onderzoek naar IL-10-producerende anti-CD19 CAR T-cellen bij r/r B-cel ALL
dec 2025 | Leukemie